CA2890217C - Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres - Google Patents

Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres Download PDF

Info

Publication number
CA2890217C
CA2890217C CA2890217A CA2890217A CA2890217C CA 2890217 C CA2890217 C CA 2890217C CA 2890217 A CA2890217 A CA 2890217A CA 2890217 A CA2890217 A CA 2890217A CA 2890217 C CA2890217 C CA 2890217C
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
actriib
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2890217A
Other languages
English (en)
Other versions
CA2890217A1 (fr
Inventor
Yifu FANG
Victor Schorr Sloan
Keith Hruska
Victoria Sung
Randall Stevens
William Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Washington University in St Louis WUSTL
Original Assignee
Celgene Corp
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Washington University in St Louis WUSTL filed Critical Celgene Corp
Priority to CA3120678A priority Critical patent/CA3120678A1/fr
Publication of CA2890217A1 publication Critical patent/CA2890217A1/fr
Application granted granted Critical
Publication of CA2890217C publication Critical patent/CA2890217C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés pour le traitement de troubles osseux qui sont associés à une maladie rénale, les procédés comprenant l'administration d'inhibiteurs d'activine-ActRIIA à un sujet ayant besoin du traitement. La présente invention concerne en outre des procédés et des compositions pour le traitement de troubles osseux de remodelage réduit, dans lesquels les procédés comprennent l'administration d'inhibiteurs d'activine-ActRIIA à un sujet ayant besoin du traitement. La présente invention concerne en outre des compositions pour le traitement de troubles osseux qui sont associés à une maladie rénale et des compositions pour le traitement de troubles osseux de remodelage réduit et de la calcification vasculaire.
CA2890217A 2012-11-02 2013-11-01 Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres Active CA2890217C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3120678A CA3120678A1 (fr) 2012-11-02 2013-11-01 Antagonistes du recepteur d'activine de type 2 et utilisations pour le traitement des os et d'autres troubles

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261721898P 2012-11-02 2012-11-02
US61/721,898 2012-11-02
US201261740665P 2012-12-21 2012-12-21
US61/740,665 2012-12-21
PCT/US2013/068009 WO2014071158A1 (fr) 2012-11-02 2013-11-01 Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3120678A Division CA3120678A1 (fr) 2012-11-02 2013-11-01 Antagonistes du recepteur d'activine de type 2 et utilisations pour le traitement des os et d'autres troubles

Publications (2)

Publication Number Publication Date
CA2890217A1 CA2890217A1 (fr) 2014-05-08
CA2890217C true CA2890217C (fr) 2021-07-20

Family

ID=50628091

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3120678A Pending CA3120678A1 (fr) 2012-11-02 2013-11-01 Antagonistes du recepteur d'activine de type 2 et utilisations pour le traitement des os et d'autres troubles
CA2890217A Active CA2890217C (fr) 2012-11-02 2013-11-01 Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3120678A Pending CA3120678A1 (fr) 2012-11-02 2013-11-01 Antagonistes du recepteur d'activine de type 2 et utilisations pour le traitement des os et d'autres troubles

Country Status (16)

Country Link
US (3) US10195249B2 (fr)
EP (3) EP3308796B1 (fr)
JP (4) JP2016504275A (fr)
KR (3) KR102279522B1 (fr)
CN (1) CN104936605A (fr)
AU (3) AU2013337677B2 (fr)
BR (1) BR112015009948B1 (fr)
CA (2) CA3120678A1 (fr)
ES (2) ES2652437T3 (fr)
HK (2) HK1214525A1 (fr)
IL (2) IL238443B (fr)
MX (2) MX366336B (fr)
NZ (1) NZ707477A (fr)
RU (2) RU2678117C2 (fr)
WO (1) WO2014071158A1 (fr)
ZA (1) ZA201503135B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20180030264A (ko) 2005-11-23 2018-03-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5237970B2 (ja) 2007-02-01 2013-07-17 アクセルロン ファーマ， インコーポレイテッド 乳癌を治療または予防するためのアクチビンＡｃｔＲＩＩａアンタゴニストおよび使用
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI459963B (zh) 2007-02-09 2014-11-11 Acceleron Pharma Inc 包含ActRIIa-Fc融合蛋白的醫藥組合物；ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途；ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
KR20210034684A (ko) 2009-06-12 2021-03-30 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MD4801C1 (ro) 2014-12-03 2022-10-31 Celgene Corporation Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
US10548976B2 (en) 2015-05-20 2020-02-04 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type II receptor ligand traps
US20180086806A9 (en) * 2016-04-06 2018-03-29 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
US10722558B2 (en) * 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
EP4026556A1 (fr) * 2016-10-05 2022-07-13 Acceleron Pharma Inc. Compositions et procédés de traitement d'une maladie rénale
EP3522912A4 (fr) * 2016-10-05 2020-10-14 Acceleron Pharma Inc. Hétéromultimères de récepteurs de type i et de type ii de la superfamille des tgf-bêta et leurs utilisations
CA3054837A1 (fr) 2017-03-24 2018-09-27 Novartis Ag Procede pour la prevention et le traitement de maladies cardiaques
CN107320718B (zh) * 2017-05-23 2020-12-11 余红 促生长激素释放激素激动剂在制备抗血管钙化药物中的应用
JP2021522795A (ja) * 2018-05-03 2021-09-02 アクセルロン ファーマ インコーポレイテッド ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用

Family Cites Families (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5078486A (en) 1989-10-13 1992-01-07 Evans David W Self-calibrating vision test apparatus
AU8761391A (en) 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
JPH06500574A (ja) 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
DE69228118T2 (de) 1991-06-25 1999-08-19 Genetics Institute Bmp-9 zusammensetzungen
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP0679163A4 (fr) 1993-01-12 1997-07-16 Univ Johns Hopkins Med Facteur-3 de croissance et de differenciation.
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
AU701623B2 (en) 1993-10-14 1999-02-04 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
DK0776337T3 (da) 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
JPH11502717A (ja) 1995-04-11 1999-03-09 ザ ジェネラル ホスピタル コーポレーション 逆ツーハイブリッドシステム
US6132988A (en) 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US20050244867A1 (en) 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
JP2001503266A (ja) 1996-10-25 2001-03-13 ジー．ディー．サール アンド カンパニー 環状に並べ替えたエリスロポイエチン受容体アゴニスト
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
WO1999006563A1 (fr) 1997-07-30 1999-02-11 Emory University Nouvelle proteine de mineralisation osseuse, adn, vecteurs et systemes d'expressions
WO1999006559A1 (fr) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Procedes d'identification des recepteurs des facteurs de differenciation de la croissance
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
CA2302525A1 (fr) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatine-3
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
KR100473836B1 (ko) 1997-10-03 2005-03-07 츄가이 세이야꾸 가부시키가이샤 천연 인간형화 항체
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US6440930B1 (en) 1998-09-17 2002-08-27 Eli Lilly And Company Protein formulations
US6656708B1 (en) 1998-09-22 2003-12-02 Long Yu Human growth differentiation factor encoding sequence and polypeptide encoded by such DNA sequence and producing method thereof
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU777783B2 (en) 1999-04-19 2004-10-28 Kyowa Hakko Kogyo Co. Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
PL356007A1 (en) 1999-11-12 2004-05-31 Maxygen Holdings Ltd Interferon gamma conjugates
CN1250288C (zh) 1999-12-15 2006-04-12 研究发展基金会 作为抑制素受体的β聚糖及其用途
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
BRPI0110914B8 (pt) 2000-05-15 2021-05-25 Hoffmann La Roche 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
EP1303605A2 (fr) 2000-07-19 2003-04-23 Eli Lilly And Company Acides nucleiques, vecteurs, cellules hotes, polypeptides et leurs utilisations
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US7048949B2 (en) 2000-11-20 2006-05-23 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
WO2002043759A2 (fr) 2000-12-01 2002-06-06 Wyeth Methode et composition permettant de moduler la croissance osseuse
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20040132675A1 (en) 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
WO2002074340A1 (fr) 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
WO2002088171A2 (fr) 2001-04-26 2002-11-07 Avidia Research Institute Banques combinatoires de domaines monomeres
EP2116259B1 (fr) 2001-05-24 2012-01-25 ZymoGenetics, Inc. Protéines de fusion d'immunoglobuline-TACI
US7074901B2 (en) 2001-05-25 2006-07-11 Serono Genetics Institute S.A. Isolated human vCOL16A1 polypeptide and fragments thereof
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
JP3888998B2 (ja) 2001-07-17 2007-03-07 帝人株式会社 ＰＰＡＲδ活性化作用を測定することを特徴とする物質の選択方法及び薬剤
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
CA2916093C (fr) 2001-12-06 2020-11-03 Fibrogen, Inc. Utilisation d'inhibiteur d'hydroxylase prolyl hif pour le traitement destroubles neurologiques
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
BR0307548A (pt) 2002-02-11 2006-01-17 Genentech Inc Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo
MXPA04008150A (es) 2002-02-21 2005-06-17 Wyeth Corp Gasp1: una proteina que contiene dominio de folistatina.
AU2003216345A1 (en) 2002-02-21 2003-09-09 Wyeth Follistatin domain containing proteins
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
WO2003087162A2 (fr) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides et procedes utilises dans la detection et le traitement du cancer
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
AU2003261246A1 (en) 2002-08-16 2004-03-03 Wyeth Bmp-2 estrogen responsive element and methods of using the same
CN1713905A (zh) 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2004064770A2 (fr) 2003-01-17 2004-08-05 Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services Utilisation d'un inhibiteur de smad3 dans le traitement d'une fibrose dependant de la transition epithelium-mesenchyme comme dans l'oeil et le rein
EP1592416B1 (fr) 2003-02-07 2009-01-07 ProMetic BioSciences Inc. Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese
US20040197828A1 (en) 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
WO2005028517A2 (fr) 2003-05-09 2005-03-31 The General Hospital Corporation PROTEINES DE FUSION SOLUBLES DU RECEPTEUR TGF- ss DE TYPE III
US7785587B2 (en) 2003-06-02 2010-08-31 Wyeth Therapeutic methods for muscular or neuromuscular disorders
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
US7611465B2 (en) 2003-07-15 2009-11-03 Board Of Regents, The University Of Texas System Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry
WO2005009460A2 (fr) 2003-07-25 2005-02-03 Medexis, S.A. Composition pharmaceutique comportant l'activine a, l'alk-4 ou leurs derives pour le traitement des troubles ophtalmiques ou du cancer
DE10335211A1 (de) 2003-08-01 2005-02-17 Robert Bosch Gmbh Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine
WO2005025601A1 (fr) 2003-09-15 2005-03-24 Monash University Isoformes de follistatine et leurs utilisations
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
DK1706428T3 (da) 2004-01-22 2009-11-30 Merck Patent Gmbh Anti-cancer-antistoffer med reduceret komplementfiksering
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
CA2561317A1 (fr) 2004-03-26 2005-10-13 Acceleron Pharma Inc. Propeptides bmp-3 et methodes associees
EP1730186A2 (fr) 2004-03-31 2006-12-13 Xencor, Inc. Variants de bmp-7 ayant des proprietes ameliorees
WO2005113590A2 (fr) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Propeptides de bmp10 et procédés correspondants
WO2006002387A2 (fr) 2004-06-24 2006-01-05 Acceleron Pharma Inc. Propeptides gdf3 et methodes associees
CA2574777C (fr) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Polypeptides du recepteur actrii, procedes et compositions correspondants
EP1794191B1 (fr) 2004-08-05 2016-05-18 The Regents of The University of California Molecules ayant un effet sur le developpement et la fonction cellulaire
JP2008509927A (ja) 2004-08-12 2008-04-03 ワイス Ｇｄｆ−８阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法
WO2006039400A2 (fr) 2004-09-29 2006-04-13 Mount Sinai School Of Medicine Of New York University Compositions et methodes modulant la fsh et le recepteur de la fsh, inhibant la resorption osseuse osteoclastique et les pertes osseuses de l'osteoporose
US7879569B2 (en) 2004-11-09 2011-02-01 The Trustees Of The University Of Pennsylvania Methods for diagnosis of myelodysplastic syndromes (MDS)
WO2006055689A2 (fr) 2004-11-16 2006-05-26 Avidia Research Institute Squelettes proteiques et leurs utilisations
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US7968091B2 (en) 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
CN101198321A (zh) 2005-04-26 2008-06-11 味之素株式会社 骨髓祖红细胞分化诱导剂
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
EP1931697B1 (fr) 2005-09-28 2010-09-15 ZymoGenetics, Inc. Antagonistes anti il-17a et anti il-17f et leurs methodes d'utilisation
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20180030264A (ko) 2005-11-23 2018-03-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
MX2008007324A (es) 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
CA2632936A1 (fr) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Composes heteroaromatiques en tant qu'inhibiteurs de stearoyl-coenzyme a delta-9 desaturase
JP2009521452A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
WO2007076127A2 (fr) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Modulateurs du facteur de croissance transformant
US7361512B2 (en) 2006-01-20 2008-04-22 Beckman Coulter, Inc. Low hemoglobin concentration cell percentage and method of use in detection of iron deficiency
EP1976377A4 (fr) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp Composés destinés au traitement des troubles du métabolisme
ATE530066T1 (de) 2006-02-28 2011-11-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
WO2007109668A2 (fr) * 2006-03-20 2007-09-27 The Uab Research Foundation Compositions et méthodes pour améliorer la masse osseuse par la modulation de nouveaux récepteurs de la parathormone et de fragments de cette dernière
WO2007120767A2 (fr) 2006-04-14 2007-10-25 Amgen Inc. Agonistes limités à durée prolongée du récepteur d'érythropoïétine
WO2007123391A1 (fr) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Intervention thérapeutique dans une maladie génétique chez un individu en modifiant l'expression d'un gène exprimé de manière aberrante.
JP2009536659A (ja) 2006-05-09 2009-10-15 ヘマクエスト・ファーマシューティカルズ，インコーポレーテッド 血液疾患の治療法
ES2382993T3 (es) 2006-07-21 2012-06-15 Lyne Laboratories, Inc. Composición líquida de acetato de calcio
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
WO2008030367A2 (fr) 2006-09-01 2008-03-13 The General Hospital Corporation Inhibiteurs sélectifs de la myostatine
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
JP5468187B2 (ja) 2006-09-26 2014-04-09 ポリプラスチックス株式会社 ポリアセタール樹脂組成物
WO2008060139A1 (fr) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Procédés destinés à contrôler la minéralisation d'une matrice extracellulaire, procédés thérapeutiques se fondant sur ces procédés et médicaments destinés à être utilisés dans le cadre de ces procédés
WO2008073292A2 (fr) 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Procédé destiné à protéger les cellules épithéliales tubulaires rénales de rcn
CA2672581A1 (fr) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
BRPI0720476B1 (pt) 2006-12-18 2022-05-31 Acceleron Pharma Inc Uso de um polipeptídeo de actrii para tratar anemia em um paciente humano
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5237970B2 (ja) 2007-02-01 2013-07-17 アクセルロン ファーマ， インコーポレイテッド 乳癌を治療または予防するためのアクチビンＡｃｔＲＩＩａアンタゴニストおよび使用
TW201940502A (zh) * 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI459963B (zh) 2007-02-09 2014-11-11 Acceleron Pharma Inc 包含ActRIIa-Fc融合蛋白的醫藥組合物；ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途；ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
WO2013106175A1 (fr) 2011-12-19 2013-07-18 Amgen Inc. Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
MX2009012934A (es) 2007-06-01 2009-12-15 Wyeth Corp Metodos y composiciones para modular la actividad de bmp-10.
WO2009009059A1 (fr) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Composés spiro en tant qu'antagonistes du tgf-bêta
EP3251694A1 (fr) 2007-08-03 2017-12-06 Summit (Oxford) Limited Combinaisons de médicaments pour le traitement de la dystrophie musculaire de duchenne
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (fr) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Peptide biologiquement actif et procédé d'utilisation correspondant
US20100279409A1 (en) 2007-09-13 2010-11-04 Neil Robson Method for modifying celluar immune resonse by modulating activin activity
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2220118A2 (fr) 2007-11-21 2010-08-25 Amgen Inc. Agents et épitopes de liaison à wise
CA2718403A1 (fr) * 2008-03-13 2009-09-17 The General Hospital Corporation Inhibiteurs de la voie de signalisation bmp
WO2009146148A2 (fr) 2008-04-04 2009-12-03 Tactair Fluid Controls, Inc. Mécanisme de verrouillage avec actionneur à double mode
WO2009137075A1 (fr) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anticorps anti-activine et leurs utilisations pour promouvoir la croissance osseuse
US20110104133A1 (en) 2008-05-06 2011-05-05 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2009146408A1 (fr) 2008-05-30 2009-12-03 Summa Health Systems Llc Procédés d'utilisation d'inhibiteurs du récepteur tgf-b ou des inhibiteurs a-83-01 et sb-431542 de kinase de type activine (alk) 5 pour traiter une maladie des yeux et la guérison de blessure
JP5778576B2 (ja) * 2008-06-26 2015-09-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストを投薬する方法および処置される患者をモニターする方法
CA2729054C (fr) * 2008-06-26 2019-09-03 Acceleron Pharma Inc. Antagonistes d'actriib et utilisations pour augmenter les taux d'erythrocytes
US8637611B2 (en) 2008-08-13 2014-01-28 Designer Molecules, Inc. Amide-extended crosslinking compounds and methods for use thereof
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
WO2010059861A1 (fr) 2008-11-20 2010-05-27 University Of Southern California Compositions et procédés de modulation de la pousse des cheveux
PT2370463T (pt) 2008-11-26 2016-11-04 Amgen Inc Variante estabilizada do receptor da activina iib
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
AU2010210033A1 (en) * 2009-02-05 2011-08-04 Digna Biotech, S.L. Pharmaceutical compositions comprising TGF- beta1 inhibitor peptides
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
JP2012524073A (ja) 2009-04-17 2012-10-11 スムマ ヘルス システムズ エルエルシー 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
WO2010125003A1 (fr) 2009-04-27 2010-11-04 Novartis Ag Compositions et procédés pour l'augmentation de la croissance des muscles
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
KR20210034684A (ko) 2009-06-12 2021-03-30 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
CN105535938B (zh) 2009-08-13 2022-04-26 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
KR20210029836A (ko) 2009-09-09 2021-03-16 악셀레론 파마 인코포레이티드 ＡｃｔＲＩＩｂ 길항제들와 이의 투약 및 용도
US20110129469A1 (en) 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
WO2012027065A2 (fr) 2010-08-27 2012-03-01 Celgene Corporation Polythérapie pour traiter des maladies
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
ES2741477T3 (es) 2011-10-17 2020-02-11 Acceleron Pharma Inc Composiciones para tratar la sobrecarga de hierro en talasemia
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (fr) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. AGENTS DE LIAISON À ActRIIB ET UTILISATIONS DE CEUX-CI
EP2771017A4 (fr) 2011-10-28 2015-04-01 Paranta Biosciences Ltd Procédé de traitement de l'hypersécrétion de mucus
US9603908B2 (en) 2012-03-30 2017-03-28 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate-2-sulfatase
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP3521310A1 (fr) 2012-06-14 2019-08-07 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Utilisation d'agents de blocage de signalisation de protéine morphogénique osseuse (bmp) pour le traitement de maladies neuro-inflammatoires et neurodégénératives
WO2014007198A1 (fr) 2012-07-02 2014-01-09 協和発酵キリン株式会社 Agent thérapeutique à base d'anticorps anti-bmp9 en tant que principe actif, pour le traitement de l'anémie, notamment une anémie rénale et une anémie liée à un cancer
EP2911682A4 (fr) 2012-10-24 2016-03-23 Celgene Corp Méthodes de traitement de l'anémie
CA2889209C (fr) 2012-10-24 2023-08-22 Celgene Corporation Biomarqueur utilisable dans le traitement de l'anemie
WO2014064292A1 (fr) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) Méthode pour la prévention ou le traitement de la fibrillation auriculaire
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
KR20210133321A (ko) 2012-11-08 2021-11-05 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
CN103047581B (zh) 2012-12-04 2015-04-01 京东方科技集团股份有限公司 背光模组及具有该背光模组的显示装置
WO2014093531A1 (fr) 2012-12-11 2014-06-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation de réparation de myofibre par une anti-myostatine dans des stratégies de cellules souches
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015022658A2 (fr) 2013-08-14 2015-02-19 Novartis Ag Procédé de traitement de la myosite à corps d'inclusion sporadique
US20160313349A1 (en) 2013-12-16 2016-10-27 Paranta Biosciences Limited Method of diagnosis and treatment
US20160333418A1 (en) 2014-01-14 2016-11-17 Santa Maria Biotherapeutics, Inc. Activin Inhibitor Response Prediction and Uses for Treatment
US20170248609A1 (en) 2014-01-27 2017-08-31 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
WO2015143403A1 (fr) 2014-03-21 2015-09-24 Acceleron Pharma, Inc. Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace par inhibition de l'activine b et/ou de gdf11
JP6601687B2 (ja) 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
EP3808778A1 (fr) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
JP2017519009A (ja) 2014-06-13 2017-07-13 サンタ マリア バイオセラピューティクス インコーポレイテッド 製剤化された受容体ポリペプチドおよび関連する方法
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MD4801C1 (ro) 2014-12-03 2022-10-31 Celgene Corporation Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
TN2017000468A1 (en) 2015-05-13 2019-04-12 Acceleron Pharma Inc TREATMENT OF BETA-THALASSEMIA USING ACTRIl LIGAND TRAPS.
US10548976B2 (en) 2015-05-20 2020-02-04 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type II receptor ligand traps
CA2994413A1 (fr) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Procedes de traitement de syndrome myeloproliferatif
WO2017079591A2 (fr) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace
CN108697793B (zh) 2015-11-23 2023-08-01 阿塞勒隆制药公司 治疗眼睛疾病的方法
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза

Also Published As

Publication number Publication date
AU2018236696A1 (en) 2018-10-18
IL267066A (en) 2019-08-29
RU2015120804A (ru) 2016-12-27
EP3308796A1 (fr) 2018-04-18
JP2020143164A (ja) 2020-09-10
ZA201503135B (en) 2019-09-25
MX2019008085A (es) 2019-09-09
NZ747422A (en) 2021-04-30
MX366336B (es) 2019-07-05
HK1214525A1 (zh) 2016-07-29
BR112015009948B1 (pt) 2022-12-06
US20230293634A1 (en) 2023-09-21
EP2914277A4 (fr) 2016-05-25
US10195249B2 (en) 2019-02-05
ES2652437T3 (es) 2018-02-02
JP2016504275A (ja) 2016-02-12
MX2015005538A (es) 2016-02-05
KR20150082423A (ko) 2015-07-15
NZ707477A (en) 2019-09-27
US20150283209A1 (en) 2015-10-08
HK1254086A1 (zh) 2019-07-12
RU2678117C2 (ru) 2019-01-23
AU2020213397A1 (en) 2020-08-27
IL238443A0 (en) 2015-06-30
IL267066B (en) 2022-02-01
AU2013337677B2 (en) 2018-06-28
WO2014071158A1 (fr) 2014-05-08
ES2884095T3 (es) 2021-12-10
AU2013337677A1 (en) 2015-05-21
EP3964224A1 (fr) 2022-03-09
KR102279522B1 (ko) 2021-07-19
CA3120678A1 (fr) 2014-05-08
JP6714646B2 (ja) 2020-06-24
RU2018145985A (ru) 2019-02-18
EP2914277A1 (fr) 2015-09-09
BR112015009948A8 (pt) 2021-10-19
JP2018168176A (ja) 2018-11-01
EP2914277B1 (fr) 2017-09-13
EP3308796B1 (fr) 2021-07-14
BR112015009948A2 (pt) 2017-07-11
KR20210091358A (ko) 2021-07-21
KR20220156979A (ko) 2022-11-28
IL238443B (en) 2019-07-31
JP2023011741A (ja) 2023-01-24
US20190262423A1 (en) 2019-08-29
CN104936605A (zh) 2015-09-23
CA2890217A1 (fr) 2014-05-08

Similar Documents

Publication Publication Date Title
US20230293634A1 (en) Activin-actrii antagonists and uses for treating bone and other disorders
AU2021258087B2 (en) Treatment of beta-thalassemia using ActRII ligand traps
AU2021212084B2 (en) Activin-ActRII antagonists and uses for treating anemia
US20190049469A1 (en) Biomarker for use in treating anemia
JP6132861B2 (ja) 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
CA2964129A1 (fr) Traitement d'une maladie cardiovasculaire a l'aide de pieges de ligands d'actrii
NZ747422B2 (en) Activin-actrii antagonists and uses for treating bone and other disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180928